IN2014DN09348A - - Google Patents

Info

Publication number
IN2014DN09348A
IN2014DN09348A IN9348DEN2014A IN2014DN09348A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A IN 9348DEN2014 A IN9348DEN2014 A IN 9348DEN2014A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09348A publication Critical patent/IN2014DN09348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Abstract

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof wherein the substituents are as those disclosed in the specification. These compounds and the pharmaceutical compositions containing them are useful for the treatment of inflammatory diseases and disorders such as for example pulmonary fibrosis...
IN9348DEN2014 2012-06-20 2013-06-17 IN2014DN09348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IN2014DN09348A true IN2014DN09348A (en) 2015-07-17

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9348DEN2014 IN2014DN09348A (en) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US9321738B2 (en)
EP (1) EP2864300A1 (en)
JP (1) JP2015520202A (en)
KR (1) KR20150021057A (en)
CN (1) CN104411692A (en)
AU (1) AU2013279512A1 (en)
BR (1) BR112014030685A2 (en)
CA (1) CA2869541A1 (en)
CL (1) CL2014003243A1 (en)
CO (1) CO7131358A2 (en)
CR (1) CR20140525A (en)
EA (1) EA201492285A1 (en)
HK (1) HK1206342A1 (en)
IL (1) IL236088A0 (en)
IN (1) IN2014DN09348A (en)
MA (1) MA37764A1 (en)
MX (1) MX2014014710A (en)
PE (1) PE20142448A1 (en)
PH (1) PH12014502789A1 (en)
SG (1) SG11201407220YA (en)
UA (1) UA109868C2 (en)
WO (1) WO2013189864A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066729A (en) 2011-08-15 2014-09-24 英特穆恩公司 Lysophosphatidic acid receptor antagonists
SG11201407228PA (en) * 2012-06-20 2014-12-30 Hoffmann La Roche N-aryltriazole compounds as lpar antagonists
WO2014145873A2 (en) 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
CN106458964B (en) 2014-06-27 2019-11-22 宇部兴产株式会社 The salt of halogen substituted heterocyclic compound
AR108838A1 (en) 2016-06-21 2018-10-03 Bristol Myers Squibb Co CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS
JP7208240B2 (en) * 2017-12-19 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー Cyclohexylate triazole azines as LPA antagonists
CN112189010A (en) * 2017-12-19 2021-01-05 百时美施贵宝公司 Triazole N-linked carbamoylcyclohexanoic acids as LPA antagonists
CN112055710A (en) 2017-12-19 2020-12-08 百时美施贵宝公司 Cyclohexyl acid pyrazole azines as LPA antagonists
KR20200101957A (en) 2017-12-19 2020-08-28 브리스톨-마이어스 스큅 컴퍼니 Isoxazole O-linked carbamoyl cyclohexyl acid as LPA antagonist
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
EA202091500A1 (en) 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани Pyrazole N-Bonded Carbamoylcyclohexyl Acids as LPA Antagonists
KR20200100722A (en) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Cyclohexyl acid isoxazole azine as an LPA antagonist
KR20200100753A (en) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Cyclohexyl acid pyrazole azole as an LPA antagonist
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
CN112041304A (en) 2017-12-19 2020-12-04 百时美施贵宝公司 Isoxazole N-linked carbamoylcyclohexanoic acids as LPA antagonists
US11319315B2 (en) * 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
AR114070A1 (en) * 2017-12-29 2020-07-15 Biomarin Pharm Inc GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF A DISEASE
CN113473985A (en) * 2018-09-18 2021-10-01 百时美施贵宝公司 Cyclopentanoic acid as LPA antagonist
CN113366000A (en) * 2018-09-18 2021-09-07 百时美施贵宝公司 Oxabicyclic acids as LPA antagonists
KR20210060547A (en) * 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Cycloheptyl acid as an LPA antagonist
CA3158743A1 (en) * 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202344504A (en) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (en) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 Compounds and compositions for treating conditions associated with lpa receptor activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
AU2011338561A1 (en) * 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
CN104066729A (en) * 2011-08-15 2014-09-24 英特穆恩公司 Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
CO7131358A2 (en) 2014-12-01
PE20142448A1 (en) 2015-01-28
EP2864300A1 (en) 2015-04-29
CA2869541A1 (en) 2013-12-27
UA109868C2 (en) 2015-10-12
MX2014014710A (en) 2015-03-04
MA37764A1 (en) 2016-01-29
CL2014003243A1 (en) 2015-03-20
HK1206342A1 (en) 2016-01-08
CN104411692A (en) 2015-03-11
WO2013189864A1 (en) 2013-12-27
CR20140525A (en) 2015-01-12
SG11201407220YA (en) 2014-12-30
BR112014030685A2 (en) 2017-06-27
JP2015520202A (en) 2015-07-16
US9321738B2 (en) 2016-04-26
KR20150021057A (en) 2015-02-27
US20150133511A1 (en) 2015-05-14
PH12014502789A1 (en) 2015-02-09
AU2013279512A1 (en) 2014-10-16
EA201492285A1 (en) 2015-04-30
IL236088A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
IN2014DN09352A (en)
IN2014DN09348A (en)
IN2014DN09347A (en)
PH12016500024A1 (en) Bromodomain inhibitor
IN2014MN02598A (en)
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2015DN01119A (en)
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
IN2014DN09434A (en)
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
MX2016002794A (en) Antiproliferative compounds.
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
IN2014DN06869A (en)
MX340574B (en) Imidazo pyrazines.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
IN2013DN02555A (en)
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2015001657A (en) Lpar - substituted cyanopyrazole compounds.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
MX2014001862A (en) 5-cycloalkyl- or 5-heterocyclyl-nicotinamides.